Progressive MS Pipeline

[zen2010]

Upon request, here are the drugs from the pipeline that are being tested for progressive forms of MS. If I've missed anything, please let me know.



Progressive MS Treatment Pipeline - September 2011

Phase 3 Trials
- Gilenya (aka FTY720 and fingolimod) (PPMS) (Novartis)
- Masitinib (SPMS and PPMS) (aka Kinavet or AB1010) (AB Science)
- Ocrelizumab (R1594) (trial for PPMS) (Genentech, Roche, Biogen)
- Revimmune (aka high dose cyclophosphamide or cytoxan) (Accentia Biopharmaceuticals) (refractory MS - includes SPMS I think, not sure about PPMS)

Phase 2 Trials
- Amiloride (Oxford University) (PPMS)
- Fluoxetine (aka Prozac) (SP, PP & RRMS) (University Medical Center Groningen)
- GEM-SP (SPMS) (Gemacbio)
- Hydroxyurea (PPMS) (S. Andrea Hospital)
- Idebenone (National Institute of Neurological Disorders and Stroke)
- Lithium (US Department of Veterans Affairs)
- Mesenchymal Stem Cells (4 trials listed in clinicaltrials.gov)
- MIS416 (progressive MS) (Innate Therapeutics)
- PI-2301 (Peptimmune)
- Pixantrone (aka BBR 2778) (SPMS) (Cell Therapeutics)
- RTL1000 (Artielle ImmunoTherapeutics)
- Zocor (aka simvastatin) (SPMS) (MS-STAT trial - UK)

Hi all,

Can anyone pls update this status?

I tried to find something on the net but didn't get anything...

Thks

[zen2010]

I found this interesting link below...
https://www.mssociety.org.uk/ms-researc ... peline#PMS

[UWE59]

I found this interesting link below...
https://www.mssociety.org.uk/ms-researc ... peline#PMS

This link is not available.

[NHE]

I found this interesting link below...
https://www.mssociety.org.uk/ms-researc ... peline#PMS

This link is not available.

It works for me when I click on it.

[zen2010]

I found this interesting link below...
https://www.mssociety.org.uk/ms-researc ... peline#PMS

This link is not available.

It works for me when I click on it.

Hi,

Forget about the previous link and try the one below:
http://www.nationalmssociety.org/Resear ... #section-0

BR

[seeva]

HI Friends please read
https://multiplesclerosisnewstoday.com/ ... -patients/
regards
seeva

[zen2010]

Hi,

The next treatment for SPMS (and also PPMS I guess) will probably be this one:
https://multiplesclerosisnewstoday.com/ ... -for-spms/

Expected in US in March 2019
Later (so I guess end of the year) in Europe

[NHE]

The next treatment for SPMS (and also PPMS I guess) will probably be this one:
https://multiplesclerosisnewstoday.com/ ... -for-spms/

Expected in US in March 2019
Later (so I guess end of the year) in Europe

Regarding Siponimod, it sounds like PML could be a potential problem.

https://multiplesclerosisnewstoday.com/ ... 2-for-spms

Siponimod works by stopping the immune cells from entering the brain and spinal cord, preventing them from causing inflammation and damage to the myelin sheath.

Siponimod does this by binding to the sphingosine-1-phosphate (S1P) receptor found on the outside of immune cells, blocking its normal action. It interacts specifically with S1P receptor 1 and 5. The S1P receptor is important to trigger the release of immune cells from the lymph node and into the circulating blood. Siponimod keeps the immune cells trapped in the lymph node, slowing MS disease progression.

and...

https://mymsaa.org/publications/msresea ... siponimod/

Siponimod is a drug with a mechanism of action similar to Gilenya. Like Gilenya, it works at the S1P receptor family to block the movement of lymph cells from lymph nodes, however, siponimod appears to interact with less of the receptors than Gilenya does – with its primary actions at the S1P1 and the S1P5 receptors. Siponimod has a relatively short half-life compared to Gilenya, which means that the drug does not stay in the body as long. Researchers hope that these small differences will minimize cardiac issues.

[CureOrBust]

Hi,

The next treatment for SPMS (and also PPMS I guess) will probably be this one:
https://multiplesclerosisnewstoday.com/ ... -for-spms/

Expected in US in March 2019
Later (so I guess end of the year) in Europe

This trial http://www.thisisms.com/forum/drug-pipe ... 30179.html has already started. I am registered for the trial, but am on a wash out period of Gilenya (ie Siponimod's older brother); 9 months, so my first dosing is in feb . They have run a previous trial using autologous cells, and previous to that, a single original trial patient. From my understanding the original single guy improved, the second trial was supposedly successful based on a company bought up the rights, and is now running an allogeneic based trial. (see link, in the link) I reiterate, this trial has already started dosing patients. I tried to get onto the second trial, but although the dr was in Australia, he only included patients from his hospital

[CureOrBust]

I finished my last dosing a number of months ago. However, I have notably progressed including a relapse. I am SPMS. I have received the second highest dosing.

I will be discussing with the trial Neuro about coming off the trial, and starting another DMD or restarting Gilenya.

Although the study is un-blinded, all the test/results are not seen until after the end of the trial. I think they want to test all the samples in one batch, so that there is no difference in the results induced by difference in testing over time. I am thinking of getting my GP to run an independent EBV test, to see if there is a change in that respect.

[NHE]

I finished my last dosing a number of months ago. However, I have notably progressed including a relapse. I am SPMS. I have received the second highest dosing.

I will be discussing with the trial Neuro about coming off the trial, and starting another DMD or restarting Gilenya.

Siponimod was recently approved as Mayzent.

viewforum.php?f=61

Its efficacy on slowing disability progression is not terribly impressive (this graph is from the prescribing information).

[ElliotB]

That graph/chart looks surprising similar to one you posted recently in an Ocrevus thread (for Ocrevus, obviously):

viewtopic.php?f=58&t=30961

Interesting...

[CureOrBust]

Siponimod was recently approved as Mayzent.

Its on my list of exit options for discussion. However, I do not think it has been approved in Australia. I think it is still under consideration of our equivalent of the FDA i.e. the TGA (Therapeutic Goods Administration) and for Govt funding under the PBA ( ie Pharmaceutical Benefits Scheme). Gilenya comes from >$2000 AUD a month down to $40 AUD a month.

PS: I am SPMS, no enhancing lesions, so Lemtrada is out.

[NHE]

That graph/chart looks surprising similar to one you posted recently in an Ocrevus thread (for Ocrevus, obviously)

The Mayzent graph appears to be either distorted or the relative risk reduction calculation was done incorrectly. If one extends horizontal lines from the treatment plots over to the y axis, I get about 43% for the control treatment and about 36% for the Mayzent treatment.



Relative risk reduction should be calculated as (controls-treated)/controls.
https://bestpractice.bmj.com/info/us/to ... late-risk/

This yields (43%-36%)/43% = 16.3% relative risk reduction.

Am I missing something? I just don't see how they got 21%.

[NHE]

Relative risk reduction should be calculated as (controls-treated)/controls.
https://bestpractice.bmj.com/info/us/to ... late-risk/

This yields (43%-36%)/43% = 16.3% relative risk reduction.

Am I missing something? I just don't see how they got 21%.

A similar analysis of the Ocrevus data plot yields...

Relative risk: (46.71-38.86)/46.71 = 16.8%

I don't see how they get the claimed 24% ???